Evidence map›Paper›PMID 41946831›Full record

ArticleBritish journal of cancer2026

Potency and safety of novel [

Jessica Pougoue Ketchemen, Alissar Monzer, Fabrice Ngoh Njotu, Hanan Babeker, Anjong Florence Tikum, Emmanuel Nwangele, Nikita Henning, Nava Hassani, Amy Futela Ngong, Alireza Doroudi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jessica Pougoue KetchemenFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada.
Alissar MonzerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Fabrice Ngoh NjotuFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada.
Hanan BabekerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Anjong Florence TikumDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Emmanuel NwangeleFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada.
Nikita HenningDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Nava HassaniDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Amy Futela NgongFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada.
Alireza DoroudiFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada.
Humphrey FongeFaculté de Pharmacie, Université Laval, Ferdinand Andry Pavillon, Québec, QC, Canada. humphrey.fonge@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0001-9388-6872

Funding

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) 408132Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) 437660
6 · The paper itself

Abstract

purposeApproved therapeutics targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) have unacceptably high recurrence rates. HER2 is amplified and overexpressed in 25-30% of BC. Actinium-225 (

aimTo evaluate the effectiveness and safety of [ EXPERIMENTAL

designThe antibody-drug conjugate (ADC) pertuzumab-PEG

resultsInternalisation in HCC1954 and JIMT-1 cells was HER2 density-dependent, with pertuzumab-PEG

conclusion[

Indexed as

ActiniumAntibodies, Monoclonal, HumanizedBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesMaytansineAdo-Trastuzumab EmtansineAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CPolyethylene GlycolsTissue DistributionXenograft Model Antitumor AssaysActiniumActinium-225Ado-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesMaytansinepertuzumabPolyethylene Glycols

Identifiers

PMID41946831
PMCPMC13226710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.